Coherus BioSciences, Inc. Earnings Recaps
Q1 2026
May 12, 2026
Coherus Oncology shares rose 11.4% post-earnings as clinical trial progress and clear data timing on key pipeline assets notably outperformed expectations, supporting confidence in upcoming catalysts and commercial execution.
Key takeaways
- Completed target patient accrual for CATALYST-202 first-line hepatocellular carcinoma study of casdozokitug; initial data expected midyear.
- Encouraging prior data showed 38% overall response rate and 17% complete response rate for casdozokitug combo, exceeding historical benchmarks for standard therapy.
- Tagmokitug expansion cohorts progressing well with planned data flow throughout second half of 2026, including multiple tumor types such as head and neck, upper GI, and esophageal cancers.
- Commercial outlook reiterates a progressive ramp to $15 million quarterly in 2026, doubling by 2027, and peaking at $44 million quarterly by 2028.
- Management remains focused on advancing the Treg depletion platform amid evolving competitive dynamics, underscoring pipeline differentiation and future partnering opportunities.
Q3 2025
Nov 8, 2025
Coherus Oncology reported strong Q3 2025 results, demonstrating significant progress in both financial metrics and clinical development, particularly with its promising pipeline of cancer therapies.
Key takeaways
- Revenue growth, driven by LOQTORZI’s successful market performance in nasopharyngeal cancer, reinforces confidence in achieving future revenue targets.
- The company has improved its balance sheet and reduced expenses, reflecting effective cost management and strategic financial planning.
- Enrollment in clinical trials is progressing well, with promising indications in multiple cancer types, setting the stage for data readouts planned for next year.
- Coherus is focusing on partnerships to enhance clinical development funding and expand the reach of its innovative Treg-depleting therapies, leveraging global rights for key assets.
- Continued advancements in Treg-targeting treatments, especially CHS-114, position Coherus at the forefront of emerging cancer therapies, following significant recognition at industry events.